Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2022; 32(04): 540-554
DOI: 10.1055/s-0042-1754361
Review Article

Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma

Pankaj Gupta 
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Naveen Kalra 
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Sreedhara B. Chaluvashetty
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Shivanand Gamangatti
2   Department of Radiodiagnosis, AIIMS, New Delhi, India
,
Amar Mukund 
3   Department of Interventional Radiology, ILBS, New Delhi, India
,
Razik Abdul
2   Department of Radiodiagnosis, AIIMS, New Delhi, India
,
VS Shyam
3   Department of Interventional Radiology, ILBS, New Delhi, India
,
Sanjay Saran Baijal
4   Department of Interventional Radiology, Medanta, Gurugram, Haryana, India
,
Chander Mohan
5   Department of Interventional Radiology, BLK Superspeciality Hospital, New Delhi, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies and a significant cause of cancer-related death. Treatment of HCC depends on the stage of the tumor. As many patients with HCC are not deemed fit for surgical resection or liver transplantation, locoregional therapies play an essential role in the management. Image-guided locoregional treatments include percutaneous ablative therapies and endovascular therapies. The choice of an individual or a combination of therapies is guided by the tumor and patient characteristics. As the outcomes of image-guided locoregional treatments depend on the ability to achieve necrosis of the entire tumor along with a safety margin around it, it is mandatory to follow standard guidelines. In this manuscript, we discuss in detail the various aspects of image-guided locoregional therapies to guide interventional radiologists involved in the care of patients with HCC.

Keywords

hepatocellular carcinoma - interventional radiologists - locoregional treatment


Publication History

Article published online:
19 September 2022

© 2022. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017; 152 (04) 812-820.e5
    CrossrefPubMedGoogle Scholar
  • 2 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol 2021; 75 (01) 108-119
    CrossrefPubMedGoogle Scholar
  • 3 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
    CrossrefPubMedGoogle Scholar
  • 4 Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol 2014; 31 (02) 180-186
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013; 30 (01) 3-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Facciorusso A, Bellanti F, Villani R. et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 2017; 5 (04) 511-518
    CrossrefPubMedGoogle Scholar
  • 7 Massarweh NN, Davila JA, El-Serag HB. et al. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res 2016; 200 (02) 552-559
    CrossrefPubMedGoogle Scholar
  • 8 Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (12) 3069-3077
    CrossrefPubMedGoogle Scholar
  • 9 Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21 (03) 327-332
    CrossrefPubMedGoogle Scholar
  • 10 Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (05) 920-925
    CrossrefPubMedGoogle Scholar
  • 11 Lencioni R, de Baere T, Burrel M. et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35 (05) 980-985
    CrossrefPubMedGoogle Scholar
  • 12 Song MJ, Park CH, Kim JD. et al. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011; 23 (06) 521-527
    CrossrefPubMedGoogle Scholar
  • 13 Sacco R, Tapete G, Simonetti N. et al. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2017; 4 (04) 105-110
    CrossrefPubMedGoogle Scholar
  • 14 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther 2016; 33 (05) 699-714
    CrossrefPubMedGoogle Scholar
  • 15 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: the best is yet to come. World J Radiol 2015; 7 (10) 306-318
    CrossrefPubMedGoogle Scholar
  • 16 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54 (08) 1151-1156
    CrossrefPubMedGoogle Scholar
  • 17 Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52 (03) 380-388
    CrossrefPubMedGoogle Scholar
  • 18 McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. Semin Intervent Radiol 2013; 30 (01) 49-55
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Izumi N, Hasegawa K, Nishioka Y. et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). J Clin Oncol 2019; 37 (15, suppl): 4002
    CrossrefGoogle Scholar
  • 20 Cucchetti A, Piscaglia F, Cescon M. et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59 (02) 300-307
    CrossrefPubMedGoogle Scholar
  • 21 Xu Q, Kobayashi S, Ye X, Meng X. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep 2014; 4: 7252
    CrossrefPubMedGoogle Scholar
  • 22 Xu XL, Liu XD, Liang M, Luo BM. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology 2018; 287 (02) 461-472
    CrossrefPubMedGoogle Scholar
  • 23 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 24 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104 (13) 1775-1784
    CrossrefPubMedGoogle Scholar
  • 25 Iezzi R, Pompili M, La Torre MF. et al; HepatoCATT Study Group for the Multidisciplinary Management of HCC. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis 2015; 47 (03) 242-248
    CrossrefPubMedGoogle Scholar
  • 26 Song MJ, Bae SH, Lee JS. et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med (Korean Assoc Intern Med) 2016; 31 (02) 242-252
    PubMedGoogle Scholar
  • 27 Xu RC, Liu HC, Li JL. et al. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma. Curr Med Res Opin 2015; 31 (08) 1553-1560
    CrossrefPubMedGoogle Scholar
  • 28 Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. World J Gastroenterol 2014; 20 (29) 10174-10182
    CrossrefPubMedGoogle Scholar
  • 29 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116 (23) 5452-5460
    CrossrefPubMedGoogle Scholar
  • 30 Tsuchiya K, Asahina Y, Tamaki N. et al. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl 2014; 20 (03) 291-297
    CrossrefPubMedGoogle Scholar
  • 31 Mazzaferro V, Battiston C, Perrone S. et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240 (05) 900-909
    CrossrefPubMedGoogle Scholar
  • 32 Brillet PY, Paradis V, Brancatelli G. et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol 2006; 186 (5, Suppl): S296-S305
    CrossrefPubMedGoogle Scholar
  • 33 Lu DS, Yu NC, Raman SS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41 (05) 1130-1137
    CrossrefPubMedGoogle Scholar
  • 34 Seo N, Kim MS, Park MS. et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with liver imaging reporting and data system version 2017. Eur Radiol 2020; 30 (01) 261-271
    CrossrefPubMedGoogle Scholar
  • 35 Liao WJ, Shi M, Chen JZ, Li AM. Local recurrence of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2010; 16 (40) 5135-5138
    CrossrefPubMedGoogle Scholar
  • 36 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012; 35 (04) 765-774
    CrossrefPubMedGoogle Scholar
  • 37 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62 (05) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 38 Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 2018; 7 (01) 104-119
    CrossrefPubMedGoogle Scholar
  • 39 Salem R, Gabr A, Riaz A. et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018; 68 (04) 1429-1440
    CrossrefPubMedGoogle Scholar
  • 40 Unzueta A, Cabrera R. Treatment options in patients awaiting liver transplantation with hepatocellular carcinoma and cholangiocarcinoma. Clin Liver Dis 2017; 21 (02) 231-251
    CrossrefPubMedGoogle Scholar
  • 41 Ohnishi K, Ohyama N, Ito S, Fujiwara K. Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid. Radiology 1994; 193 (03) 747-752
    CrossrefPubMedGoogle Scholar
  • 42 Mauro MA, Murphy KPJ, Thomson KR, Venbrux AC, Morgan RA. Image-Guided Interventions E-Book: Expert Radiology Series. Edinburgh, London: Elsevier Health Sciences; 2013: 1842
    Google Scholar
  • 43 Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27 (01) 67-72
    CrossrefPubMedGoogle Scholar
  • 44 Schlag PM, Stein US. Regional Cancer Therapy. Berlin/Heidelberg, Germany: Springer Science; 2007: 455
    CrossrefGoogle Scholar
  • 45 Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000; 174 (02) 323-331
    CrossrefPubMedGoogle Scholar
  • 46 Tatli S, Acar M, Tuncali K, Morrison PR, Silverman S. Percutaneous cryoablation techniques and clinical applications. Diagn Interv Radiol 2010; 16 (01) 90-95
    PubMedGoogle Scholar
  • 47 Charpentier KP. Irreversible electroporation for the ablation of liver tumors: are we there yet?. Arch Surg 2012; 147 (11) 1053-1061
    CrossrefPubMedGoogle Scholar
  • 48 Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms—review article. Röfo Fortschr Geb Röntgenstr Nuklearmed 2017; 189 (11) 1055-1066
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Cannon R, Ellis S, Hayes D, Narayanan G, Martin II RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107 (05) 544-549
    CrossrefPubMedGoogle Scholar
  • 50 Kalra N, Gupta P, Gorsi U. et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience. Cardiovasc Intervent Radiol 2019; 42 (04) 584-590
    CrossrefPubMedGoogle Scholar
  • 51 Jin B, Wang D, Lewandowski RJ. et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196 (04) 919-928
    CrossrefPubMedGoogle Scholar
  • 52 Kim YJ, Raman SS, Yu NC, Lu DSK. MR-guided percutaneous ethanol injection for hepatocellular carcinoma in a 0.2T open MR system. J Magn Reson Imaging 2005; 22 (04) 566-571
    CrossrefPubMedGoogle Scholar
  • 53 Sudheendra D, Léger R, Groppo ER. et al. Comparison of three different needles for percutaneous injections. Cardiovasc Intervent Radiol 2007; 30 (01) 151-152
    CrossrefPubMedGoogle Scholar
  • 54 Livraghi T, Lazzaroni S, Pellicanò S, Ravasi S, Torzilli G, Vettori C. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. AJR Am J Roentgenol 1993; 161 (05) 1065-1069
    CrossrefPubMedGoogle Scholar
  • 55 Kuang M, Lu M-D, Xie XY. et al. Ethanol ablation of hepatocellular carcinoma Up to 5.0cm by using a multipronged injection needle with high-dose strategy. Radiology 2009; 253 (02) 552-561
    CrossrefPubMedGoogle Scholar
  • 56 Marelli L, Stigliano R, Triantos C. et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (01) 6-25
    CrossrefPubMedGoogle Scholar
  • 57 Boulin M, Delhom E, Pierredon-Foulongne MA, Cercueil JP, Guiu B. Transarterial chemoembolization for hepatocellular carcinoma: an old method, now flavor of the day. Diagn Interv Imaging 2015; 96 (06) 607-615
    CrossrefPubMedGoogle Scholar
  • 58 Dezarn WA, Cessna JT, DeWerd LA. et al; American Association of Physicists in Medicine. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 2011; 38 (08) 4824-4845
    CrossrefPubMedGoogle Scholar
  • 59 TheraSphere Yttrium-90 microspheres package insert. Kanata CMN. Accessed May 9, 2022 at: http://www.therasphere.com/physicians-package-insert/TS_PackageInsert_USA_v12.pdf
    Google Scholar
  • 60 SIR-Spheres Yttrium-90 microspheres package insert. Singapore Science Park SSM. Accessed July 26, 2022 at: https://www.sirtex.com/ap/products/sir-spheres-y-90-resin-microspheres/
    Google Scholar
  • 61 Piana PM, Bar V, Doyle L. et al. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford) 2014; 16 (04) 336-341
    CrossrefPubMedGoogle Scholar
  • 62 Liu DM, Salem R, Bui JT. et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16 (07) 911-935
    CrossrefPubMedGoogle Scholar
  • 63 Hamoui N, Minocha J, Memon K. et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol 2013; 24 (11) 1743-1745
    CrossrefPubMedGoogle Scholar
  • 64 Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006; 23 (01) 64-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Lau WY, Kennedy AS, Kim YH. et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012; 82 (01) 401-407
    CrossrefPubMedGoogle Scholar
  • 66 Garin E, Rolland Y, Edeline J. et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 2015; 56 (03) 339-346
    CrossrefPubMedGoogle Scholar
  • 67 Odisio BC, Richter M, Aloia TA. et al. Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 2016; 20 (08) 1428-1434
    CrossrefPubMedGoogle Scholar
  • 68 Lee LH, Hwang JI, Cheng YC. et al. Comparable outcomes of ultrasound versus computed tomography in the guidance of radiofrequency ablation for hepatocellular carcinoma. PLoS One 2017; 12 (01) e0169655
    CrossrefPubMedGoogle Scholar
  • 69 Yuan C, Yuan Z, Cui X. et al. Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma. J Cancer Res Ther 2019; 15 (04) 784-792
    CrossrefPubMedGoogle Scholar
  • 70 Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226 (02) 441-451
    CrossrefPubMedGoogle Scholar
  • 71 Zhang M, Liang P, Cheng ZG, Yu XL, Han ZY, Yu J. Efficacy and safety of artificial ascites in assisting percutaneous microwave ablation of hepatic tumours adjacent to the gastrointestinal tract. Int J Hyperthermia 2014; 30 (02) 134-141
    CrossrefPubMedGoogle Scholar
  • 72 Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009; 19 (11) 2630-2640
    CrossrefPubMedGoogle Scholar
  • 73 Hermida M, Cassinotto C, Piron L. et al. Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. Int J Hyperthermia 2018; 35 (01) 90-96
    CrossrefPubMedGoogle Scholar
  • 74 Liao M, Zhong X, Zhang J. et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: a prospective randomized trial. J Surg Oncol 2017; 115 (08) 971-979
    CrossrefPubMedGoogle Scholar
  • 75 Lencioni RA, Allgaier HP, Cioni D. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228 (01) 235-240
    CrossrefPubMedGoogle Scholar
  • 76 Shiina S, Teratani T, Obi S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129 (01) 122-130
    CrossrefPubMedGoogle Scholar
  • 77 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004; 127 (06) 1714-1723
    CrossrefPubMedGoogle Scholar
  • 78 Lencioni R, Cioni D, Crocetti L. et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234 (03) 961-967
    CrossrefPubMedGoogle Scholar
  • 79 Lee MW, Kang D, Lim HK. et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma <3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020; 30 (04) 2391-2400
    CrossrefPubMedGoogle Scholar
  • 80 Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, Ferko N, Amaral JF. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol 2019; 17 (01) 98
    CrossrefPubMedGoogle Scholar
  • 81 Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther 2016; 7 (04) 477-489
    CrossrefPubMedGoogle Scholar
  • 82 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-year survival after surgical microwave ablation for hepatocellular carcinoma: a single-center experience in Japan. Ann Surg Oncol 2019; 26 (12) 4126-4133
    CrossrefPubMedGoogle Scholar
  • 83 Wang C, Wang H, Yang W. et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61 (05) 1579-1590
    CrossrefPubMedGoogle Scholar
  • 84 Rong G, Bai W, Dong Z. et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One 2015; 10 (04) e0123065
    CrossrefPubMedGoogle Scholar
  • 85 Zhou L, Yang YP, Feng YY. et al. Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Chin J Cancer 2009; 28 (01) 45-48
    Google Scholar
  • 86 Gupta P, Maralakunte M, Kumar-M P. et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol 2021; 31 (07) 5400-5408
    CrossrefPubMedGoogle Scholar
  • 87 Mafeld S, Wong JJ, Kibriya N. et al. Percutaneous irreversible electroporation (IRE) of hepatic malignancy: a bi-institutional analysis of safety and outcomes. Cardiovasc Intervent Radiol 2019; 42 (04) 577-583
    CrossrefPubMedGoogle Scholar
  • 88 Takayasu K, Arii S, Ikai I. et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131 (02) 461-469
    CrossrefPubMedGoogle Scholar
  • 89 Takayasu K, Arii S, Kudo M. et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56 (04) 886-892
    CrossrefPubMedGoogle Scholar
  • 90 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 91 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52 (05) 1741-1749
    CrossrefPubMedGoogle Scholar
  • 92 Sangro B, Carpanese L, Cianni R. et al; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54 (03) 868-878
    CrossrefPubMedGoogle Scholar
  • 93 Soydal C, Arslan MF, Kucuk ON, Idilman R, Bilgic S. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. Nucl Med Commun 2016; 37 (06) 646-649
    CrossrefPubMedGoogle Scholar
  • 94 Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends 2015; 9 (05) 289-298
    CrossrefPubMedGoogle Scholar
  • 95 Di Stasi M, Buscarini L, Livraghi T. et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 1997; 32 (11) 1168-1173
    CrossrefPubMedGoogle Scholar
  • 96 Clark TWI, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13 (9 Pt 2): S245-S252
    CrossrefPubMedGoogle Scholar
  • 97 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015; 1: CD006745
    PubMedGoogle Scholar
  • 98 Goto E, Tateishi R, Shiina S. et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J Clin Gastroenterol 2010; 44 (05) 374-380
    CrossrefPubMedGoogle Scholar
  • 99 Sainani NI, Silverman SG, Tuna IS. et al. Incidence and clinical sequelae of portal and hepatic venous thrombosis following percutaneous cryoablation of liver tumors. Abdom Radiol (NY) 2016; 41 (05) 970-977
    CrossrefPubMedGoogle Scholar
  • 100 Kim R, Kang TW, Cha DI. et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol 2019; 29 (02) 654-662
    CrossrefPubMedGoogle Scholar
  • 101 Distelmaier M, Barabasch A, Heil P. et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins. Radiology 2017; 285 (03) 1023-1031
    CrossrefPubMedGoogle Scholar
  • 102 Gupta P, Maralakunte M, Sagar S. et al. Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis. Eur Radiol 2021; 31 (09) 6511-6521
    CrossrefPubMedGoogle Scholar
  • 103 Marcacuzco Quinto A, Nutu OA, San Román Manso R. et al. Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. Cir Esp (Engl Ed) 2018; 96 (09) 560-567
    Google Scholar
  • 104 Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006; 23 (02) 119-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 105 Bajpai S, Kambadakone A, Guimaraes AR, Arellano RS, Gervais DA, Sahani D. Image-guided treatment in the hepatobiliary system: role of imaging in treatment planning and posttreatment evaluation. Radiographics 2015; 35 (05) 1393-1418
    CrossrefPubMedGoogle Scholar
  • 106 Zheng SG, Xu HX, Lu MD. et al. Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (06) 855-865
    CrossrefPubMedGoogle Scholar
  • 107 Lim HK, Choi D, Lee WJ. et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221 (02) 447-454
    CrossrefPubMedGoogle Scholar
  • 108 Gupta P, Kalra N, Gulati A. et al. Response assessment following image-guided therapy of hepatocellular carcinoma. J Clin Interven Radiol 2020; 4: 88-97
    Article in Thieme ConnectGoogle Scholar
  • 109 Boas FE, Do B, Louie JD. et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015; 26 (01) 69-73
    CrossrefPubMedGoogle Scholar
  • 110 Fu Y, Zhao X, Yun Q. et al. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8 (07) 10388-10400
    PubMedGoogle Scholar
  • 111 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (24) 3872-3882
    CrossrefPubMedGoogle Scholar
  • 112 Abdelaziz AO, Abdelmaksoud AH, Nabeel MM. et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 2017; 18 (01) 189-194
    PubMedGoogle Scholar
  • 113 Jinhua H. RCT of TAE with Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma. Natl Lib Med 2021
    Google Scholar
  • 114 Zhang YJ, Liang HH, Chen MS. et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007; 244 (02) 599-607
    CrossrefPubMedGoogle Scholar
  • 115 Kudo M, Imanaka K, Chida N. et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47 (14) 2117-2127
    CrossrefPubMedGoogle Scholar
  • 116 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64 (05) 1090-1098
    CrossrefPubMedGoogle Scholar
  • 117 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2 (08) 565-575
    CrossrefPubMedGoogle Scholar
  • 118 Kudo M, Ueshima K, Ikeda M. et al; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69 (08) 1492-1501
    CrossrefPubMedGoogle Scholar